Related Experiment Videos
Pathophysiological principles of the relation between myocardial hypertrophy of the left ventricle and its regression
1Department of Pathophysiology, Medical Faculty, Bratislava, Slovak Republic.
Insights
Left ventricular hypertrophy, while increasing heart performance, is a risk factor for cardiac events. Its regression is not always therapeutic and depends on various factors, requiring careful management.
Area of Science:
- Cardiology
- Physiology
- Pathophysiology
Background:
- Left ventricular hypertrophy (LVH) results from hemodynamic overload, offering functional benefits but posing risks.
- LVH is associated with increased cardiac morbidity and mortality.
- Regression of LVH is a potential therapeutic goal, but its success is complex.
Purpose of the Study:
- To evaluate the biological value and therapeutic implications of left ventricular hypertrophy regression.
- To determine factors influencing the success and risks of LVH reversal.
- To clarify the role of hypertrophy regression within the broader management of cardiac overload.
Main Methods:
- Analysis of the biological implications of hypertrophy and its regression.
- Consideration of the influence of hypertrophy type and duration of overload.
- Examination of regression methods and their impact on cardiovascular risk.
Main Results:
- LVH regression is not universally beneficial and its therapeutic value is context-dependent.
- Preserved or improved function post-regression does not guarantee reduced cardiovascular risk.
- Disproportionate regression of hypertrophy relative to hemodynamic overload can be detrimental, potentially leading to heart failure.
Conclusions:
- Regression of myocardial hypertrophy should not be the primary therapeutic objective.
- Management should focus on addressing the underlying hemodynamic overload.
- The ultimate goal is to ensure optimal peripheral perfusion and prevent cardiac workload from limiting survival.
Abstract:
Hypertrophy of the left heart ventricle as a consequence of a haemodynamic overload is a process of ambiguous biological value. Although hypertrophy allows to increase the performance of the ventricle without substantial elevation in wall tension, it represents a risk factor of cardiac morbidity and mortality. The regression of hypertrophy seems to be a rational outcome of this ambivalent situation. Not every reversal of hypertrophied muscle mass, however, can be unambiguously considered therapeutic success. The biological value of hypertrophy regression depends on the type of hypertrophy, on the level of deterioration of the heart by a long-lasting haemodynamic overload, as well as on the way in which the reversal of hypertrophy is achieved. Even in the case when functional characteristics are preserved or even improved compared to the hypertrophied heart, hypertrophy regression need not automatically mean a decrease of the cardiovascular risk induced by ventricular hypertrophy. Regression of hypertrophy may be even disadvantageous in those situations when reduction of hypertrophy and reduction of the haemodynamic overload proceed in a disproportional manner. Spontaneously developing regression of the hypertrophied left ventricle as demonstrated on the model of aortal insufficiency, is an explicitly pathological state, resulting in heart failure. Regression of myocardial hypertrophy should not be considered the primary therapeutic aim but rather a part of the management of haemodynamic overload of the heart. The main aim is to achieve optimal perfusion of the periphery, yet at the same time to provide such conditions which would prevent the working load of the heart to become a limiting factor of survival.